Original ContributionOxidative damage in Parkinson disease: Measurement using accurate biomarkers
Section snippets
Study population
Consecutive patients with PD and community-based age-matched healthy controls were recruited from the outpatient Movement Disorders Clinic after written patient consent and approval from the ethics committee of the National University Hospital, Singapore, were obtained. Clinical information (including age, gender, ethnicity, medical history, weight and height, and smoking status) was collected using standardized questionnaires. PD patients were diagnosed according to the UK Parkinson Disease
Clinical characteristics
Sixty-one cases and 61 controls were included in this study. Comparison between the demographic characteristics (such as age, gender, race, and body mass index) and medical histories of the study population did not reveal significant differences between cases and controls (Table 1). Fifteen (24%) patients were classified as in stage 1 of the Hoehn–Yahr severity scale, 26 (42%) in stage 2, 10 (16%) in stage 3, and 11 (18%) in stages 4 and 5. The mean age of PD onset was 64 ± 6 years and the mean
Discussion
Oxidative stress, characterized by an imbalance between exposure to free radicals or other reactive species and antioxidant defenses, has been implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer and Parkinson disease [13], [14], [16], [17], [18], [19], [40], [41] and it may be related to changes in mitochondrial function and protein clearance [2], [40], [41]. In this study, the systemic rise in multiple markers (such as plasma F2-IsoPs, HETEs, 7β-and
Acknowledgments
We are grateful to Professor Jason Morrow, Dr. Ginger Milne, and the Eicosanoid Core Laboratory at Vanderbilt University for providing the standards for neuroprostane measurement. We are grateful to the Biomedical Research Council (Grant 03/1/21/18/213) and National Medical Research Council (Grant NMRC/1157/2008) for their generous support of this study.
References (58)
- et al.
Lipid peroxidation as cause of nigral cell death in Parkinson disease
Lancet
(1986) - et al.
Systemic increase of oxidative nucleic acid damage in Parkinson disease and multiple system atrophy
Neurobiol. Dis.
(2002) - et al.
Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson disease
Neurosci. Lett.
(2003) - et al.
Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson disease: relationship to clinical data
J. Neurol. Sci.
(1999) - et al.
Plasma lipid peroxidation in sporadic Parkinson disease: role of the L-dopa
J. Neurol. Sci.
(2006) - et al.
2nd. Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases
J. Biol. Chem
(2006) - et al.
Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment
Atherosclerosis
(1997) - et al.
Oxidative damage in dengue fever
Free Radic. Biol. Med.
(2009) - et al.
Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid
J. Biol. Chem
(1998) - et al.
Quantification of F-ring isoprostane-like compounds (F4-neuroprostanes) derived from docosahexaenoic acid in vivo in humans by a stable isotope dilution mass spectrometric assay
J. Chromatogr. B Anal. Technol. Biomed. Life Sci
(2004)
Measurement of F2-isoprostanes, hydroxyeicosatetraenoic products, and oxysterols from a single plasma sample
Free Radic. Biol. Med.
Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A-and CD36-independent process that involves cellular proteoglycans
J. Biol. Chem.
roup V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions
Biochim. Biophys. Acta
Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein
J. Biol. Chem
Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein
J. Biol. Chem.
Protective effect of bromocriptine against BH4-induced Cath.a cell death involving up-regulation of antioxidant enzymes
Neurosci. Lett.
Recent developments in analytical methodology for 8-hydroxy-2′-deoxyguanosine and related products
J. Chromatogr. B Anal. Technol. Biomed. Life Sci
Evaluation of brain perfusion SPECT using an easy Z-score imaging system (eZIS) as an adjunct to early-diagnosis of neurodegenerative diseases
J. Neurol. Sci.
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients
Neurosci. Lett.
DJ-1 and prevention of oxidative stress in Parkinson disease and other age-related disorders
Free Radic. Biol. Med.
walk through the management of Parkinson's disease
Ann. Acad. Med. Singapore
Oxidative stress in Parkinson disease: a mechanism of pathogenic and therapeutic significance
Ann. N. Y. Acad. Sci.
Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice
J. Neurochem.
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase
Proc. Natl. Acad. Sci. USA
Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson disease and with dementia with Lewy body disease
J. Neurochem.
Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study
Mov. Disord.
generalised increase in protein carbonyls in the brain in Parkinson but not incidental Lewy body disease
J. Neurochem.
Oxidative damage in nucleic acids and Parkinson disease
J. Neurosci. Res
Overview of the extranigral aspects of Parkinson disease
Arch. Neurol.
Cited by (214)
Plasma oxylipin profiles reflect Parkinson's disease stage
2024, Prostaglandins and Other Lipid MediatorsUnraveling the impact of 27-hydroxycholesterol in autoimmune diseases: Exploring promising therapeutic approaches
2023, Pathology Research and PracticeLipid mediated brain disorders: A perspective
2023, Prostaglandins and Other Lipid MediatorsOxysterols: From redox bench to industry
2022, Redox Biology